- Home
- FROG vs APLS Comparison
FROG vs APLS Comparison
Compare FROG & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FROG | APLS |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.2B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FROG | APLS |
|---|---|---|
| Price | $70.25 | $41.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 21 |
| Target Price | ★ $65.75 | $33.59 |
| AVG Volume (30 Days) | 2.3M | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.59 | ★ 112.50 |
| EPS | N/A | ★ 0.15 |
| Revenue | $531,840,000.00 | ★ $1,003,782,000.00 |
| Revenue This Year | $20.37 | N/A |
| Revenue Next Year | $16.99 | $18.19 |
| P/E Ratio | ★ N/A | $273.30 |
| Revenue Growth | 24.12 | ★ 28.46 |
| 52 Week Low | $34.05 | $16.10 |
| 52 Week High | $70.43 | $41.14 |
Technical Indicators
Market Signals| Indicator | FROG | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 82.93 | 85.15 |
| Support Level | $55.65 | $19.29 |
| Resistance Level | $70.43 | N/A |
| Average True Range (ATR) | 2.87 | 0.06 |
| MACD | 2.07 | -0.71 |
| Stochastic Oscillator | 93.31 | 55.56 |
Price Performance
Historical ComparisonAbout FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from united states and also has its presence in Israel, India and other regions.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).